Drew M Pardoll
Overview
Explore the profile of Drew M Pardoll including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
259
Citations
60412
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zeng Z, Zhang T, Zhang J, Li S, Connor S, Zhang B, et al.
Nat Commun
. 2025 Feb;
16(1):1070.
PMID: 39900903
Identifying tumor-specific T cell clones that mediate immunotherapy responses remains challenging. Mutation-associated neoantigen (MANA) -specific CD8+ tumor-infiltrating lymphocytes (TIL) have been shown to express high levels of CXCL13 and CD39...
2.
Yang B, Rutkowski N, Ruta A, Gray-Gaillard E, Maestas D, Kelly S, et al.
bioRxiv
. 2025 Jan;
PMID: 39868312
Significance Statement: The foreign body response to implants leads to chronic inflammation and fibrosis that can be highly variable in the general patient population. Here, we demonstrate that gut dysbiosis...
3.
Topalian S, Pardoll D
J Immunother Cancer
. 2025 Jan;
13(1.
PMID: 39855712
Neoadjuvant (presurgical) anti-programmed cell death protein-1 (PD-1)-based immunotherapy as a new approach to cancer treatment has been developing on an accelerated trajectory since the seminal clinical trial results from studies...
4.
Shen L, Zhang Y, Li Z, Zhang X, Gao X, Liu B, et al.
Nat Med
. 2025 Jan;
PMID: 39843940
Programmed cell death protein-1 (PD-1) inhibitors plus chemotherapy have been the standard of care in the first-line treatment of advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma; however, the survival benefits...
5.
Rosner S, Connor S, Sanber K, Zahurak M, Zhang T, Gurumurthy I, et al.
Clin Cancer Res
. 2024 Nov;
31(2):339-351.
PMID: 39545922
Purpose: Co-mutations of the Kirsten rat sarcoma virus (KRAS) and serine/threonine kinase 11 (STK11) genes in advanced non-small cell lung cancer (NSCLC) are associated with immune checkpoint blockade (ICB) resistance....
6.
Shaikh F, Lee S, White J, Zhao Y, Ferri J, Pereira G, et al.
Cancers (Basel)
. 2024 Nov;
16(21).
PMID: 39518082
: Preclinical and clinical data indicate that chemoradiotherapy (CRT) in combination with checkpoint inhibitors may prime an anti-tumor immunological response in esophageal cancer. However, responses to neoadjuvant therapy can vary...
7.
Sloan L, Sen R, Liu C, Doucet M, Blosser L, Katulis L, et al.
Front Immunol
. 2024 Sep;
15:1438044.
PMID: 39346903
Introduction: This is a prospective, rigorous inquiry into the systemic immune effects of standard adjuvant chemoradiotherapy, for WHO grade 4, glioblastoma. The purpose is to identify peripheral immunologic effects never...
8.
Zhang L, Maalouf A, Makri S, Banerjee J, Suru A, Tam A, et al.
Clin Cancer Res
. 2024 Sep;
30(23):5459-5472.
PMID: 39321200
Purpose: Malignant peripheral nerve sheath tumors (MPNST) are aggressive soft-tissue sarcomas and the leading cause of mortality in individuals with neurofibromatosis type 1 (NF1). Despite many clinical trials, outcomes for...
9.
Pant A, Jain A, Chen Y, Patel K, Saleh L, Tzeng S, et al.
Cancer Immunol Res
. 2024 Aug;
12(11):1542-1558.
PMID: 39133127
Regulatory T cells (Treg) are important players in the tumor microenvironment. However, the mechanisms behind their immunosuppressive effects are poorly understood. We found that CCR6-CCL20 activity in tumor-infiltrating Tregs is...
10.
Jackson C, Pant A, Dinalankara W, Choi J, Jain A, Nitta R, et al.
Immunity
. 2024 Aug;
57(8):1864-1877.e9.
PMID: 39111315
Tumor-infiltrating lymphocyte (TIL) hypofunction contributes to the progression of advanced cancers and is a frequent target of immunotherapy. Emerging evidence indicates that metabolic insufficiency drives T cell hypofunction during tonic...